Wang Qian, Ma Junfen, Jiang Zhiyun, Wu Fan, Ping Jiedan, Ming Liang
Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, China.
Medicine (Baltimore). 2017 Jun;96(24):e7173. doi: 10.1097/MD.0000000000007173.
Acute myocardial infarction (AMI) is one of the leading causes of mortality and morbidity worldwide. Recently, several studies have revealed the diagnostic value of circulating microRNAs (miRNAs) for AMI detection. However, the diagnostic capacity of miRNAs for AMI is still controversial due to the inconsistent results among studies.
A systematic literature search was conducted to retrieve relevant articles in PubMed and other databases up to February 2017. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) were used to assess the overall test performance of miRNAs. Subgroup analysis was conducted to explore the potential sources of heterogeneity. We evaluated the publication bias by the Deeks' funnel plot asymmetry test and all statistical analyses were performed using Meta-disc 1.4 and Stata software.
A total of 26 articles comprising 1973 AMI patients and 1236 healthy controls were included in this meta-analysis. The overall pooled diagnostic data was as follows: the pooled sensitivity of 0.76 (95% confidence interval [CI]: 0.75-0.78), the pooled specificity of 0.82 (95% CI: 0.81-0.84), the pooled PLR of 4.68 (95% CI: 3.92-5.59), the pooled NLR of 0.28 (95% CI: 0.25-0.32), and the pooled DOR of 18.66 (95% CI: 14.11-24.68). The AUC value was 0.8661 in the overall summary receiver operator characteristic curve. Subgroup analysis indicated that miRNA-499 had better diagnostic accuracy over other miRNAs.
MiRNAs may serve as promising diagnostic biomarkers in the early diagnosis of AMI. Further studies were needed to evaluate the diagnostic value of miRNAs for AMI before clinical application.
急性心肌梗死(AMI)是全球范围内导致死亡和发病的主要原因之一。最近,多项研究揭示了循环微小RNA(miRNA)在AMI检测中的诊断价值。然而,由于研究结果不一致,miRNA对AMI的诊断能力仍存在争议。
进行系统的文献检索,以检索截至2017年2月在PubMed和其他数据库中的相关文章。采用合并敏感度、特异度、阳性似然比(PLR)、阴性似然比(NLR)、诊断比值比(DOR)和曲线下面积(AUC)来评估miRNA的整体检测性能。进行亚组分析以探索异质性的潜在来源。我们通过Deeks漏斗图不对称性检验评估发表偏倚,所有统计分析均使用Meta-disc 1.4和Stata软件进行。
本荟萃分析共纳入26篇文章,包括1973例AMI患者和1236例健康对照。总体合并诊断数据如下:合并敏感度为0.76(95%置信区间[CI]:0.75 - 0.78),合并特异度为0.82(95%CI:0.81 - 0.84),合并PLR为4.68(95%CI:3.92 - 5.59),合并NLR为0.28(95%CI:0.25 - 0.32),合并DOR为18.66(95%CI:14.11 - 24.68)。在总体汇总的受试者工作特征曲线中,AUC值为0.8661。亚组分析表明,miRNA - 499比其他miRNA具有更好的诊断准确性。
miRNA可能是AMI早期诊断中有前景的诊断生物标志物。在临床应用之前,需要进一步研究评估miRNA对AMI的诊断价值。